Psilocybe Cubensis (Photo: afgooey74)
On Saturday, President Donald Trump signed an executive order directing federal agencies to speed up research into psychedelic drugs. The announcement comes as the VA continues searching for better treatment options for Veterans living with PTSD.
According to reporting from multiple sources, the order pushes for faster reviews and more federal backing for studies on substances like psilocybin and ibogaine. These drugs are being studied as possible treatments for PTSD, depression, and anxiety. The plan also sets aside $50 million to support research and expand access if the treatments are shown to be safe.
The VA is already involved in several clinical trials in California, New York, and Oregon. These studies focus on Veterans who have not seen results from standard treatments and continue to face ongoing challenges managing PTSD and related conditions.
Mental health remains a serious issue for Veterans. PTSD, depression, and anxiety are common, especially among those who have experienced combat or repeated deployments. Traditional treatments such as medication and therapy help many, but not all. Some Veterans continue to deal with symptoms even after trying multiple approaches. That reality has led to growing interest in alternatives that could work differently from existing treatments.
Some early findings have given researchers a reason to keep studying these drugs. In studies involving Veterans, treatments using ibogaine have been tied to improvements in PTSD symptoms, along with depression, anxiety, and traumatic brain injury. A small study connected to researchers in California followed Veterans who received treatment outside the U.S. and reported reduced symptoms. The study was limited and did not include a placebo group, so the findings are still considered early.
Still, questions remain about safety and oversight. PBS and CNN reported that ibogaine has been linked to serious heart risks and remains unapproved by the FDA. Other psychedelics, including LSD and MDMA, are still being studied, and some have faced delays in the approval process while regulators ask for more data.
Veterans’ groups like The American Legion have helped keep attention on the issue. Coverage from NPR and PBS has stated how those experiences continue to shape the conversation, even as researchers call for larger, controlled studies to better understand safety and long-term effects.
For now, the VA’s role in these trials places it at the center of what could become a new direction in mental health care for Veterans. The outcome of ongoing research could influence how PTSD and related conditions are treated in the years ahead.
Author: Rikki Almanza
Rikki is a Web Content Coordinator for the American Legion, Department of California. With a deep-rooted family connection to the military, Rikki is committed to using her skills and knowledge to provide valuable assistance and resources to servicemembers and veterans.
